Evidence map›Paper›PMID 36029315›Full record

SynthesisKnee surgery, sports traumatology, arthroscopy : official journal of the ESSKA2022

Limited evidence of adjuvant biologics with bone marrow stimulation for the treatment of osteochondral lesion of the talus: a systematic review.

Dexter Seow, Hugo A Ubillus, Mohammad T Azam, Nathaniel Mercer, Youichi Yasui, James Hui, Christopher J Pearce, John G Kennedy

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Advancements in the treatment of osteochondral lesions of the talus.Journal of orthopaedic surgery and research · 2024
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Dexter SeowNYU Langone Health, NYU Langone Orthopedic Hospital, New York, New York, USA.ORCID http://orcid.org/0000-0003-1769-9244
Hugo A UbillusNYU Langone Health, NYU Langone Orthopedic Hospital, New York, New York, USA.
Mohammad T AzamNYU Langone Health, NYU Langone Orthopedic Hospital, New York, New York, USA.
Nathaniel MercerNYU Langone Health, NYU Langone Orthopedic Hospital, New York, New York, USA.
Youichi YasuiDepartment of Orthopaedic Surgery, School of Medicine, Teikyo University, Tokyo, Japan.
James HuiNational University Health System, Singapore, Singapore.
Christopher J PearceNational University Health System, Singapore, Singapore.
John G KennedyNYU Langone Health, NYU Langone Orthopedic Hospital, New York, New York, USA. john.kennedy@nyulangone.org.
New York University Langone Orthopedic Hospital · USNational University of Singapore · SGTeikyo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the complication rates, continuous functional outcome scores, and return to play data following bone marrow stimulation (BMS) versus biologics ± BMS for the treatment of osteochondral lesion of the talus (OLT).

methodsA systematic review was performed. The PubMed and Embase databases were searched using specific search terms and eligibility criteria according to the PRISMA guidelines. The level of evidence was assessed using published criteria by The Journal of Bone & Joint Surgery, and the quality of evidence using the Modified Coleman Methodology Score. Continuous variables were presented as mean ± standard deviation and categorical variables as frequencies (percentages).

resultsBMS versus BMS + hyaluronic acid (HA): no complications in either treatment arm were reported. The mean American Orthopaedic Foot and Ankle Society score was 43.5 to 67.3 points and 44.0 to 72.4 points, respectively. The mean 10 mm Visual Analogue Scale pain score was 7.7 to 3.8 points and 7.5 to 2.5 points, respectively. BMS versus BMS + concentrated bone marrow aspirate (CBMA): the pooled overall complication rate was 17/64 (26.6%) versus 11/71 (15.5%), respectively (non-significant). The pool revision rate was 15/64 (23.4%) versus 6/71 (8.5%), respectively (p = 0.016). There has been a notable poor reporting of complication rates for the use of ADSC and PRP as adjuvant biological therapies to BMS for the treatment of OLT.

conclusionThere was an overall limited comparative clinical evidence of adjuvant biologics with BMS versus BMS alone for the treatment of OLT. BMS + HA and BMS + CBMA can provide superior outcomes, albeit the currently limited evidence. Further studies are warranted to establish the true clinical superiority of the various biologics ± BMS versus BMS alone. These studies must also compare the various biologics against one another to determine, if any, the optimal biologic for OLT. Clinicians should counsel patients accordingly on these findings as required. LEVEL OF EVIDENCE: Level III.

Indexed as

Biological ProductsCartilage, ArticularOrthopedicsTalusBone MarrowHumansHyaluronic AcidTreatment OutcomeBiological ProductsHyaluronic AcidCartilageDrillMicrofractureSubchondral bone

Identifiers

PMID36029315
OpenAlexW4293796395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.